Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genes

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Jamal, Salma ^a,b   Goyal, Sukriti ^a,b   Shanker, Asheesh ^c   Grover, Abhinav ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b BANASTHALI UNIVERSITY   (India)

^c CENTRAL UNIVERSITY OF SOUTH BIHAR   (India)

Author keywords

Alzheimer associated genes; Functional annotations; Interaction networks; Machine learning; Molecular docking; Molecular dynamics; Sequence features

Indexed keywords

BLOOD CLOTTING FACTOR 7; DAVUNETIDE; JANUS KINASE 2; PHOSPHOLIPASE C GAMMA2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VINCULIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ARTICLE; BAYES NET; BAYESIAN LEARNING; BINDING AFFINITY; CALCULATION; CARD8 GENE; CDH1 GENE; CLASSIFICATION; CLASSIFIER; CONTROLLED STUDY; DECISION TABLE; F7 GENE; FUNCTIONAL TREE; GENE; GENE INTERACTION; GENE ONTOLOGY; GENETIC ASSOCIATION; HUMAN; ITSN1 GENE; J48; JAK2 GENE; LOCALLY WEIGHTED LEARNING; LOGISTIC REGRESSION ANALYSIS; MACHINE LEARNING; MM/GBSA CALCULATION; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NAIVE BAYES TREE; NFKBIA GENE; PLCG2 GENE; PROTEIN PROTEIN INTERACTION; RANDOM FOREST; RB1 GENE; RHOA GENE; RIPK3 GENE; STAT5A GENE; SUPPORT VECTOR MACHINE; SWISS-PROT; TUBB GENE; VCL GENE; BIOLOGY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INFORMATION PROCESSING; METABOLISM; MOLECULAR GENETICS; PROCEDURES; PROTEIN ANALYSIS; REPRODUCIBILITY;

ALZHEIMER DISEASE; COMPUTATIONAL BIOLOGY; DATASETS AS TOPIC; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MACHINE LEARNING; MOLECULAR SEQUENCE ANNOTATION; PROTEIN INTERACTION MAPPING; REPRODUCIBILITY OF RESULTS;

EID: 84992458508     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-016-3108-1     Document Type: Article

References (102)

1. Burns A, Iliffe S. Alzheimer's disease. BMJ. 2009;338:b158.
2. Lemkul JA, Bevan DR. The role of molecular simulations in the development of inhibitors of amyloid beta-peptide aggregation for the treatment of Alzheimer's disease. ACS Chem Neurosci. 2012;3(11):845-56.
3. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013;6(1):19-33.
4. Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP. The economical impact of dementia. Presse Med. 2005;34(1):35-41.
5. Rafii MS, Aisen PS. Advances in Alzheimer's disease drug development. BMC Med. 2015;13:62.
6. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377(9770):1019-31.
7. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2015.
8. Chung SJ, Jung Y, Hong M, Kim MJ, You S, Kim YJ, Kim J, Song K. Alzheimer's disease and Parkinson's disease genome-wide association study top hits and risk of Parkinson's disease in Korean population. Neurobiol Aging. 2013;34(11):2695. e2691-2697.
9. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science. 2008;322(5903):881-8.
10. Furney SJ, Higgins DG, Ouzounis CA, Lopez-Bigas N. Structural and functional properties of genes involved in human cancer. BMC Genomics. 2006;7:3.
11. Li Y, Xu J, Ju H, Xiao Y, Chen H, Lv J, Shao T, Bai J, Zhang Y, Wang L, et al. A network-based, integrative approach to identify genes with aberrant co-methylation in colorectal cancer. Mol Biosyst. 2014;10(2):180-90.
12. Ostlund G, Lindskog M, Sonnhammer EL. Network-based Identification of novel cancer genes. Mol Cell Proteomics. 2010;9(4):648-55.
13. Liu W, Xie H. Predicting potential cancer genes by integrating network properties, sequence features and functional annotations. Sci China Life Sci. 2013;56(8):751-7.
14. Vanunu O, Magger O, Ruppin E, Shlomi T, Sharan R. Associating genes and protein complexes with disease via network propagation. PLoS Comput Biol. 2010;6(1), e1000641.
15. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011;39(Database issue):D52-7.
16. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics. 2005;21(9):2076-82.
17. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258-61.
18. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli L, Cesareni G. MINT: the Molecular INTeraction database. Nucleic Acids Res. 2007;35(Database issue):D572-4.
19. Bader GD, Betel D, Hogue CW. BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res. 2003;31(1):248-50.
20. Hermjakob H, Montecchi-Palazzi L, Lewington C, Mudali S, Kerrien S, Orchard S, Vingron M, Roechert B, Roepstorff P, Valencia A, et al. IntAct: an open source molecular interaction database. Nucleic Acids Res. 2004;32(Database issue):D452-5.
21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.
22. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008;24(2):282-4.
23. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 2004;32(Database issue):D115-9.
24. Kuo WL, Montag AG, Rosner MR. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. Endocrinology. 1993;132(2):604-11.
25. Olson SA. EMBOSS opens up sequence analysis. European Molecular Biology Open Software Suite. Brief Bioinform. 2002;3(1):87-91.
26. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):3.
27. Priyadarsini RP, Valarmathi ML, Sivakumari S. Gain Ratio Based Feature Selection Method For Privacy Preservation. ICTACT J Soft Comput. 2011;01(04):2229-6956.
28. Novakovic J. Using Information Gain Attribute Evaluation to Classify Sonar Targets. In: 17th Telecommunications forum TELFOR. Belgrade; 2009. http://2009.telfor.rs/files/radovi/10_60.pdf.
29. Novaković J, Strbac P, Bulatović D. Toward Optimal Feature Selection Using Ranking Methods And Classification Algorithms. Yugosl J Oper Res. 2011;21(2011):119-35.
30. Hall MA. Correlation-based Feature Selection for Machine Learning. Hamilton: The University of Waikato; 1999.
31. Kira K, Rendell LA. A Practical Approach to Feature Selection. In: International Conference on Machine Learning. 1992: 249-56.
32. Bouckaert RR, Frank E, Hall MA, Holmes G, Pfahringer B, Reutemann P, Witten IH. WEKA-Experiences with a Java Open-Source Project. J Mach Learn Res. 2010;11:2533-41.
33. Lê S, Josse J, Husson F. FactoMineR: An R Package for Multivariate Analysis. J Stat Softw. 2008;25(1):1-18.
34. Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Softw. 2008;28(5):1-26.
35. Jamal S, Goyal S, Shanker A, Grover A. Checking the STEP-Associated Trafficking and Internalization of Glutamate Receptors for Reduced Cognitive Deficits: A Machine Learning Approach-Based Cheminformatics Study and Its Application for Drug Repurposing. PLoS One. 2015;10(6), e0129370.
36. Friedman N, Geiger D, Goldszmidt M. Bayesian Network Classifiers. Mach Learn. 1997;29:131-63.
37. Kohavi R. Scaling Up the Accuracy of Naive-Bayes Classifiers: a Decision-Tree Hybrid. In: Han ES WJ, editor. Menlo Park: Proceedings of the Second International Conference on Knowledge Discovery and Data Mining, vol. 7. 1996; p. 202-07.
38. Jensen FV. An Introduction to Bayesian Networks, vol. 30. UCL Press; 1996.
39. Farid, DM, Harbi N, Rahman MZ. Combining Naive Bayes and Decision Tables for Adaptive Intrusion Detection. IJNSA. 2010;2(2):12-25.
40. Breiman L. Random forests. Mach Learn. 2001;45(1):5-32.
41. Quinlan JR. C4.5: Programs for Machine Learning. 1993.
42. Gama J. Functional Trees. Mach Learn. 2004;55:219-50.
43. Atkeson CG, Moore AW, Schaal S. Locally Weighted Learning. Artif Intell Rev. 1997;11:11-73.
44. Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform. 2002;35(5-6):352-9.
45. Corinna Cortes VV. Support-Vector Networks. Mach Learn. 1995;20(3):273-97.
46. Wahi D, Jamal S, Goyal S, Singh A, Jain R, Rana P, Grover A. Cheminformatics models based on machine learning approaches for design of USP1/UAF1 abrogators as anticancer agents. Syst Synth Biol. 2015;9(1-2):33-43.
47. Jain R, Jamal S, Goyal S, Wahi D, Singh A, Grover A. Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches. Comb Chem High Throughput Screen. 2015;18(9):881-91.
48. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011;39(Database issue):D1035-41.
49. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-49.
50. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750-9.
51. Schrodinger. Schrodinger Software Suite. New York: Schrodinger LLC; 2011.
52. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S, et al. The Protein Data Bank. Acta Crystallogr D Biol Crystallogr. 2002;58(Pt 6 No 1):899-907.
53. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221-34.
54. Nagpal N, Goyal S, Wahi D, Jain R, Jamal S, Singh A, Rana P, Grover A. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease. Gene. 2015;570(1):115-21.
55. Gupta A, Jamal S, Goyal S, Jain R, Wahi D, Grover A. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease. BMC Bioinformatics. 2015;16 Suppl 19:S10.
56. Schrodinger, LigPrep. New York: 23 Schrodinger LLC; 2009.
57. Sinha S, Tyagi C, Goyal S, Jamal S, Somvanshi P, Grover A. Fragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia. J Biomol Struct Dyn. 2015; 34(10):1-39.
58. Desmond. Schrödinger Desmond Molecular Dynamics System in Maestro-Desmond Interoperability Tools. 34 ed. New York; 2013.
59. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. J Phys Chem B. 2001;105(28):6474-87.
60. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J Am Chem Soc. 1996;118(45):11225-36.
61. Prime. New York: Schrodinger LLC; 2011.
62. Xu J, Li Y. Discovering disease-genes by topological features in human protein-protein interaction network. Bioinformatics. 2006;22(22):2800-5.
63. Tu Z, Wang L, Xu M, Zhou X, Chen T, Sun F. Further understanding human disease genes by comparing with housekeeping genes and other genes. BMC Genomics. 2006;7:31.
64. Gandhi TK, Zhong J, Mathivanan S, Karthick L, Chandrika KN, Mohan SS, Sharma S, Pinkert S, Nagaraju S, Periaswamy B, et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet. 2006;38(3):285-93.
65. Wang X, Zhang D. Alzheimer's disease related-genes and apoptosis. Sheng Li Ke Xue Jin Zhan. 2001;32(4):307-11.
66. Lauss M, Kriegner A, Vierlinger K, Noehammer C. Characterization of the drugged human genome. Pharmacogenomics. 2007;8(8):1063-73.
67. Bakheet TM, Doig AJ. Properties and identification of human protein drug targets. Bioinformatics. 2009;25(4):451-7.
68. Uemura K, Lill CM, Banks M, Asada M, Aoyagi N, Ando K, Kubota M, Kihara T, Nishimoto T, Sugimoto H, et al. N-cadherin-based adhesion enhances Abeta release and decreases Abeta42/40 ratio. J Neurochem. 2009;108(2):350-60.
69. Parisiadou L, Fassa A, Fotinopoulou A, Bethani I, Efthimiopoulos S. Presenilin 1 and cadherins: stabilization of cell-cell adhesion and proteolysis-dependent regulation of transcription. Neurodegener Dis. 2004;1(4-5):184-91.
70. Baki L, Marambaud P, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Shioi J, Koo E, Ozawa M, Friedrich Jr VL, et al. Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci U S A. 2001;98(5):2381-6.
71. Asada-Utsugi M, Uemura K, Noda Y, Kuzuya A, Maesako M, Ando K, Kubota M, Watanabe K, Takahashi M, Kihara T, et al. N-cadherin enhances APP dimerization at the extracellular domain and modulates Abeta production. J Neurochem. 2011;119(2):354-63.
72. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003;8(4):345-52.
73. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology. 2007;32(11):2393-404.
74. Wei W, Norton DD, Wang X, Kusiak JW. Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain. 2002;125(Pt 9):2036-43.
75. Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, Fafouri A, Dournaud P, Gressens P, Collingridge GL, Peineau S. The role of JAK-STAT signaling within the CNS. JAKSTAT. 2013;2(1), e22925.
76. Chiba T, Yamada M, Aiso S. Targeting the JAK2/STAT3 axis in Alzheimer's disease. Expert Opin Ther Targets. 2009;13(10):1155-67.
77. Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, Aiso S. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol Psychiatry. 2009;14(2):206-22.
78. Marwarha G, Prasanthi JR, Schommer J, Dasari B, Ghribi O. Molecular interplay between leptin, insulin-like growth factor-1, and beta-amyloid in organotypic slices from rabbit hippocampus. Mol Neurodegener. 2011;6(1):41.
79. Natarajan C, Sriram S, Muthian G, Bright JJ. Signaling through JAK2-STAT5 pathway is essential for IL-3-induced activation of microglia. Glia. 2004;45(2):188-96.
80. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94(6):2642-7.
81. Oka S, Kamata H, Kamata K, Yagisawa H, Hirata H. N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett. 2000;472(2-3):196-202.
82. Frandsen A, Schousboe A. Excitatory amino acid-mediated cytotoxicity and calcium homeostasis in cultured neurons. J Neurochem. 1993;60(4):1202-11.
83. Oliveira TG, Di Paolo G. Phospholipase D in brain function and Alzheimer's disease. Biochim Biophys Acta. 2010;1801(8):799-805.
84. Keating DJ, Chen C, Pritchard MA. Alzheimer's disease and endocytic dysfunction: clues from the Down syndrome-related proteins, DSCR1 and ITSN1. Ageing Res Rev. 2006;5(4):388-401.
85. Sengar AS, Wang W, Bishay J, Cohen S, Egan SE. The EH and SH3 domain Ese proteins regulate endocytosis by linking to dynamin and Eps15. EMBO J. 1999;18(5):1159-71.
86. Kubo T, Yamaguchi A, Iwata N, Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag. 2008;4(3):605-15.
87. Lu Q, Longo FM, Zhou H, Massa SM, Chen YH. Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem. 2009;16(11):1355-65.
88. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112-9.
89. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325(5938):332-6.
90. Lau P, de Strooper B. Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol. 2010;21(7):768-73.
91. Zovoilis A, Agbemenyah HY, Agis-Balboa RC, Stilling RM, Edbauer D, Rao P, Farinelli L, Delalle I, Schmitt A, Falkai P, et al. microRNA-34c is a novel target to treat dementias. EMBO J. 2011;30(20):4299-308.
92. Monaco 3rd EA. Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. Curr Alzheimer Res. 2004;1(1):33-8.
93. Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33(37):14645-59.
94. Puig B, Ferrer I, Luduena RF, Avila J. BetaII-tubulin and phospho-tau aggregates in Alzheimer's disease and Pick's disease. J Alzheimers Dis. 2005;7(3):213-20. discussion 255-262.
95. Caramelli P, Nitrini R, Maranhao R, Lourenco AC, Damasceno MC, Vinagre C, Caramelli B. Increased apolipoprotein B serum concentration in Alzheimer's disease. Acta Neurol Scand. 1999;100(1):61-3.
96. Kelly BL, Vassar R, Ferreira A. Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem. 2005;280(36):31746-53.
97. Xu J, Kurup P, Nairn AC, Lombroso PJ. Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease. Adv Pharmacol. 2012;64:303-25.
98. Assaraf MI, Diaz Z, Liberman A, Miller Jr WH, Arvanitakis Z, Li Y, Bennett DA, Schipper HM. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol. 2007;66(5):389-98.
99. Grilli M, Ribola M, Alberici A, Valerio A, Memo M, Spano P. Amyloid Precursor Protein (APP) Gene Expression is Controlled by a NFkB/Rel Related Protein, vol. 44. NewYork: Springer US; 1995.
100. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19(2):124-34.
101. Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimers Res Ther. 2014;6(1):8.
102. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport. 2004;15(6):955-9.